Two separate policy signals emerged from FDA-facing coverage: the agency is moving toward easing restrictions on certain compounded peptides while also setting out a policy agenda that would make pediatric priority review vouchers permanent. Coverage notes FDA plans advisory panel meetings to reconsider whether compounding pharmacies should be allowed to make peptides after earlier restrictions. The proposal comes amid continued political and regulatory focus on pharmaceutical compounding and manufacturing oversight. Separately, reporting on FDA budget plans indicates an effort to broaden pediatric priority review vouchers and remove industry influence from advisory committees, framed as part of an agency policy wish list. Together, the items underscore how FDA’s near-term regulatory tools—compounding enforcement and priority voucher mechanics—could reshape product development incentives and promotional or manufacturing compliance expectations across biotech.